Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in cynomolgus monkeys

Transplantation

Volumn 98, Issue 3, 2014, Pages 267-276

  Song, Lijun ^a   Ma, Anlun ^a   Dun, Hao ^a   Hu, Yanxin ^a   Zeng, Lin ^b   Bai, Jieying ^b   Zhang, Guangzhou ^b   Kinugasa, Fumitaka ^c   Sudo, Yuji ^d   Miyao, Yasuhiro ^d   Okimura, Kazumichi ^e   Miura, Toru ^e   Daloze, Pierre ^a   Chen, Huifang ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d ASTELLAS PHARMA INC   (Japan)

^e KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

ASKP1240; Costimulation blockade; Kidney transplantation; Nonhuman primate

Indexed keywords

ASKP 1240; CREATININE; DRUG ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROGEN; TACROLIMUS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; GRAFT SURVIVAL; HAPLORHINI; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MIXED LYMPHOCYTE REACTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; SURVIVAL TIME; UREA NITROGEN BLOOD LEVEL;

ALLOGRAFTS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD40 LIGAND; CYTOKINES; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MACACA FASCICULARIS; MALE; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 84906101917     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000236     Document Type: Article

References (37)

1. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165: 302.
2. Jenkins MK, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 1988; 140: 3324.
3. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002; 109: 295.
4. Eliopoulos AG, Davies C, Knox PG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000; 20: 5503.
5. Pype S, Declercq W, Ibrahimi A, et al. TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation. J Biol Chem 2000; 275: 18586.
6. Li XL, Ménoret S, Le Mauff B, et al. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation 2008; 86: 10.
7. Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229: 152.
8. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
9. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560.
10. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
11. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114. (Pubitemid 30082329)
12. Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in Cynomolgus monkey renal allotransplantation. Transplantation 2004; 77: 717.
13. Koyama I, Kawai T, Andrews D, et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004; 77: 460.
14. Kirk AD, Knechtle SJ, Sollinger HW, et al. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation [abstract]. Am J Transplant 2001; 1(Suppl 1): 191.
15. André P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247.
16. Crow AR, Leytin V, Starkey AF, et al. CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost 2003; 1: 850.
17. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75: 637.
18. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74: 933.
19. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in Cynomolgus monkeys. Transplantation 2007; 84: 1020.
20. Badell IR, Thompson PW, Turner AP, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 2012; 12: 126.
21. Page A, Srinivasan S, Singh K, et al. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHCdefined rhesus macaque transplant model. Am J Transplant 2012; 12: 115.
22. van der Pol W, van de Winkel JG. IgG receptor polymorphisms: Risk factors for disease. Immunogenetics 1998; 48: 222.
23. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in Cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 2009; 9: 1732.
24. Watanabe M, Yamashita K, Suzuki T, et al. Long-term acceptance of islet allografts by ASKP1240 (4D11), a fully human anti-CD40 monoclonal antibody in Cynomolgus monkeys [abstract]. Am J Transplant 2011; 11(Suppl 2): 80.
25. Oura T, Yamashita K, Suzuki T, et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am J Transplant 2012; 12: 1740.
26. Ma A, Dun H, Song L, et al. Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys. Transplantation 2014; 97: 397.
27. Song L, Qi S, Dun H, et al. Surgical complications in kidney transplantation in nonhuman primates. Microsurgery 2010; 30: 327.
28. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorsparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
29. Barbari AG, Stephan AG, Masri MA. Calcineurin inhibitor-free protocols: Risks and benefits. Saudi J Kidney Dis Transpl 2007; 18: 1.
30. Kinugasa F, Nagatomi I, Ishikawa H, et al. Efficacy of oral treatment with tacrolimus in the renal transplant model in Cynomolgus monkeys. J Pharmacol Sci 2008; 108: 529.
31. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101: 2886.
32. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a fiveyear longitudinal study. Am J Transplant 2007; 7: 864.
33. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876.
34. Goldwater R, Keirns J, Blahunka P, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant 2013; 13: 1040.
35. Qi S, Xu D, Peng J, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono-and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 1275.
36. Chen H, Peng J, Luo H, et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation 2000; 69: 1555.
37. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.